切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2025, Vol. 11 ›› Issue (02) : 134 -138. doi: 10.3877/cma.j.issn.2096-1537.2025.02.006

学科建设

重症医学的多组学和表型:改变学科发展模式
杨穗碧1, 杨杰1, 周鹏敏1, 陈棚棚1, 沈鸿杰1, 薛栋2, 章仲恒1,3,4,5,()   
  1. 1. 310000 杭州,浙江大学医学院附属邵逸夫医院急诊医学科
    2. 200237 上海,华东理工大学信息科学与工程学院
    3. 310000 杭州,浙江省腹腔感染精准诊疗重点实验室
    4. 321036 浙江绍兴,绍兴文理学院医学院
    5. 323799 浙江丽水,龙泉产业创新研究院
  • 收稿日期:2025-01-19 出版日期:2025-05-28
  • 通信作者: 章仲恒
  • 基金资助:
    国家自然科学基金项目(62173147,82272180,82472243)国家重点研发计划项目(2023YFC3603104,2022YFC2504503)国家中医药管理局科技司-浙江省中医药管理局共建科技计划项目(GZY-ZJ-K1-24082)浙江省医药卫生科技计划项目(2024KY1099)浙江省基础公益研究计划 浙江省自然科学基金华东医药联合基金/重大项目(LHDMD24H150001)浙江大学龙泉创新中心项目(ZJDXLQCXZCJBGS2024016)

Multomics and phenotyping:redefining the development model of critical care medicine

Suibi Yang1, Jie Yang1, Pengmin Zhou1, Pengpeng Chen1, Hongjie Shen1, Dong Xue2, Zhongheng Zhang1,3,4,5,()   

  1. 1. Department of Emergency Medicine,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310000,China
    2. School of Information Science and Engineering,East China University of Science and Technology,Shanghai 200237,China
    3. Zhejiang Provincial Key Laboratory of Precision Diagnosis and Treatment of Abdominal Infections,Hangzhou 310000,China
    4. School of Medicine,Shaoxing University,Shaoxing 321036,China
    5. Longquan Industrial Innovation Research Institute,Lishui 323799,China
  • Received:2025-01-19 Published:2025-05-28
  • Corresponding author: Zhongheng Zhang
引用本文:

杨穗碧, 杨杰, 周鹏敏, 陈棚棚, 沈鸿杰, 薛栋, 章仲恒. 重症医学的多组学和表型:改变学科发展模式[J/OL]. 中华重症医学电子杂志, 2025, 11(02): 134-138.

Suibi Yang, Jie Yang, Pengmin Zhou, Pengpeng Chen, Hongjie Shen, Dong Xue, Zhongheng Zhang. Multomics and phenotyping:redefining the development model of critical care medicine[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2025, 11(02): 134-138.

重症医学是一个多学科和跨专业的专业,致力于全面管理患有或有风险发展为急性、危及生命的器官功能障碍的患者。长期以来,该学科面临着多种急危重综合征异质性的重大挑战,这一难题导致随机对照试验在相关疾病研究中屡屡受挫,对群体的治疗效果进行探索难以识别一种有效的治疗手段。本文将探讨多组学数据与表型的深度融合为重症医学发展带来的新契机。这种融合能够全方位、多维度地揭示重症综合征的分子机制与临床特征,精准识别不同患者亚群的病理生理差异,从而为制定个体化治疗方案提供坚实可靠的依据。这不仅有效破解了异质性难题,还显著提升了治疗效果与预后水平,推动重症医学学科发展模式从传统的基于群体疗效的探索模式向个体化精准医疗模式转变。展望未来,重症医学将更加倚重多组学技术和大数据分析,有望实现对重症患者的精准诊疗管理,进一步提高重症医学的诊疗水平,为危重患者带来更多的希望与福音。

Critical care medicine is a multidisciplinary and interprofessional specialty committed to the comprehensive management of patients with or at risk of developing acute,life-threatening organ dysfunction.Over the years,the field has faced the significant challenge of the heterogeneity of various critical syndromes,which has led to repeated setbacks in randomized controlled trials in the study of related diseases,making it difficult to identify effective treatments through population-based efficacy exploration.This review explores how the deep integration of multi-omics data and phenotypes has brought new opportunities for developing critical care medicine.This integration can reveal the molecular mechanisms and clinical characteristics of essential syndromes in an all-round and multi-dimensional manner,accurately identify the pathophysiological differences among different patient subgroups,and thus provide a solid and reliable basis for formulating individualized treatment plans.This not only effectively solves the problem of heterogeneity,but also significantly improves the therapeutic effects and prognosis,promoting the development model of the critical care medicine discipline to shift from the traditional population-based therapeutic effect exploration model to the individualized precision medical model.Looking to the future,critical care medicine will rely more on multi-omics technologies and big data analysis and is expected to achieve precise diagnosis and treatment management for critically ill patients,further improving the diagnostic and therapeutic level of critical care medicine and bringing more hope and blessings to critically ill patients.

1
刘大为.重症医学:基础到临床的艰难历程——从Sepsis 3.0 说起[J].中国实用内科杂志,2018,38(11):981-983,988.
2
于乐成,陈成伟.规范临床实践指南制定,让患者得到最优同质化治疗 [J].肝脏,2024,29(8):887-888.
3
Naithani N,Sinha S,Misra P,et al.Precision medicine:concept and tools [J].Med J Armed Forces India,2021,77(3):249-257.
4
Kneyber M,Khemani RG,Bhalla A,et al.Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome [J].Lancet Respir Med,2023,11(2):197-212.
5
Font MD,Thyagarajan B,Khanna AK.Sepsis and septic shock -basics of diagnosis,pathophysiology and clinical decision making [J].Med Clin North Am,2020,104(4):573-585.
6
GBD 2019 Antimicrobial Resistance Collaborators.Global mortality associated with 33 bacterial pathogens in 2019:a systematic analysis for the Global Burden of Disease Study 2019 [J].Lancet,2022,400(10369):2221-2248.
7
Shah RD,Wunderink RG.Viral pneumonia and acute respiratory distress syndrome [J].Clin Chest Med,2017,38(1):113-125.
8
Meyer NJ,Gattinoni L,Calfee CS.Acute respiratory distress syndrome[J].Lancet,2021,398(10300):622-637.
9
Kalil AC,Thomas PG.Influenza virus-related critical illness:pathophysiology and epidemiology [J].Crit Care,2019,23(1):258.
10
Khemani RG,Smith L,Lopez-Fernandez YM,et al.Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE):an international,observational study [J].Lancet Respir Med,2019,7(2):115-128.
11
Ghazaly M,Abu Faddan NH,Raafat DM,et al.Acute viral bronchiolitis as a cause of pediatric acute respiratory distress syndrome[J].Eur J Pediatr,2021,180(4):1229-1234.
12
石庆玲,郭卫东,徐振兴.不同病原体类型脓毒症患者的临床特征及对预后的影响因素 [J].中国病原生物学杂志,2024,19(11):1317-1321,1326.
13
Messina JA,Thaden JT,Sharma-Kuinkel BK,et al.Impact of bacterial and human genetic variation on Staphylococcus aureus infections [J].PLoS Pathog,2016,12(1):e1005330.
14
Beitler JR,Thompson BT,Baron RM,et al.Advancing precision medicine for acute respiratory distress syndrome [J].Lancet Respir Med,2022,10(1):107-120.
15
Matthay MA,Zemans RL,Zimmerman GA,et al.Acute respiratory distress syndrome [J].Nat Rev Dis Primers,2019,5(1):18.
16
Calfee CS,Delucchi KL,Sinha P,et al.Acute respiratory distress syndrome subphenotypes and differential response to simvastatin:secondary analysis of a randomised controlled trial [J].Lancet Respir Med,2018,6(9):691-698.
17
Caironi P,Tognoni G,Masson S,et al.Albumin replacement in patients with severe sepsis or septic shock [J].N Engl J Med,2014,370(15):1412-1421.
18
Venkatesh B,Finfer S,Cohen J,et al.Adjunctive glucocorticoid therapy in patients with septic shock [J].N Engl J Med,2018,378(9):797-808.
19
Fowler AA 3rd,Truwit JD,Hite RD,et al.Effect of vitamin c infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure:the CITRISALI randomized clinical trial [J].JAMA,2019,322(13):1261-1270.
20
Maslove DM,Lamontagne F,Marshall JC,et al.A path to precision in the ICU [J].Crit Care,2017,21(1):79.
21
王玉珠,王骏,黄钦.亚组分析在药物临床试验中的运用 [J].中国临床药理学杂志,2012,28(6):477-480.
22
孙同文,张西京,黎毅敏,等.中国成人急性呼吸窘迫综合征(ARDS)诊断与非机械通气治疗指南(2023) [J].中国研究型医院,2023,10(5):9-24.
23
陈国昇,文大林,种慧敏,等.尿源性脓毒症患者免疫细胞亚群及其功能指标的动态变化 [J].临床泌尿外科杂志,2024,39(5):431-437,442.
24
Ye Z,Sarkar CA.Towards a quantitative understanding of cell identity[J].Trends Cell Biol,2018,28(12):1030-1048.
25
Vaara ST,Bhatraju PK,Stanski NL,et al.Subphenotypes in acute kidney injury:a narrative review [J].Crit Care,2022,26(1):251.
26
Bhatraju PK,Zelnick LR,Herting J,et al.Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy [J].Am J Respir Crit Care Med,2019,199(7):863-872.
27
Calfee CS,Delucchi K,Parsons PE,et al.Subphenotypes in acute respiratory distress syndrome:latent class analysis of data from two randomised controlled trials [J].Lancet Respir Med,2014,2(8):611-620.
28
Famous KR,Delucchi K,Ware LB,et al.Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy [J].Am J Respir Crit Care Med,2017,195(3):331-338.
29
National Heart,Lung,and Blood Institute ARDS Clinical Trials Network; Truwit JD,Bernard GR,Steingrub J,et al.Rosuvastatin for sepsis-associated acute respiratory distress syndrome [J].N Engl J Med,2014,370(23):2191-2200.
30
LaRosa SP,Opal SM.Biomarkers:the future [J].Crit Care Clin,2011,27(2):407-419.
31
Schoettler N,Strek ME.Recent advances in severe asthma:from phenotypes to personalized medicine [J].Chest,2020,157(3):516-528.
32
Alipanah N,Calfee CS.Phenotyping in acute respiratory distress syndrome:state of the art and clinical implications [J].Curr Opin Crit Care,2022,28(1):1-8.
33
李金连,朱兵,王君艳.外周血多基因联合对脓毒症患者的诊断价值研究 [J].临床急诊杂志,2024,25(9):496-502.
34
Ho J,Lucy M,Krokhin O,et al.Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass:a nested case-control study [J].Am J Kidney Dis,2009,53(4):584-595.
35
Chen Q,Liang X,Wu T,et al.Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis [J].J Transl Med,2022,20(1):123.
36
Gutmann C,Takov K,Burnap SA,et al.SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care [J].Nat Commun,2021,12(1):3406.
37
Zhang Z,Chen L,Sun B,et al.Identifying septic shock subgroups to tailor fluid strategies through multi-omics integration [J].Nat Commun,2024,15(1):9028.
38
Berg G,Rybakova D,Fischer D,et al.Microbiome definition re-visited:old concepts and new challenges [J].Microbiome,2020,8(1):103.
39
Wei X,Guo L,Cai H,et al.MASS cohort:multicenter,longitudinal,and prospective study of the role of microbiome in severe pneumonia and host susceptibility [J].Imeta,2024,3(4):e218.
40
Montassier E,Kitsios GD,Radder JE,et al.Robust airway microbiome signatures in acute respiratory failure and hospital-acquired pneumonia[J].Nat Med,2023,29(11):2793-2804.
41
Dickson RP,Singer BH,Newstead MW,et al.Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome [J].Nat Microbiol,2016,1(10):16113.
42
Liu Z,Li N,Fang H,et al.Enteric dysbiosis is associated with sepsis in patients [J].FASEB J,2019,33(11):12299-12310.
43
Haak BW,Wiersinga WJ.The role of the gut microbiota in sepsis [J].Lancet Gastroenterol Hepatol,2017,2(2):135-143.
[1] 沈拓, 朱峰. 异质性耐药在烧伤非发酵革兰氏阴性杆菌感染中的意义[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(01): 75-80.
[2] 戴睿, 张亮, 陈浏阳, 张永博, 吴丕根, 孙华, 杨盛, 孟博. 肠道菌群与椎间盘退行性变相关性的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 546-549.
[3] 王思卓, 段晓鑫, 陈隆, 董胜利. 肠道微生物群、血液代谢物和胃癌的因果关系:东亚人群中介孟德尔随机化研究[J/OL]. 中华普通外科学文献(电子版), 2025, 19(03): 163-168.
[4] 叶春幸, 丘国清, 林缓卿, 申严, 陈思达, 赖育庭, 徐香琴. 宏基因组二代测序肺结核及病原体特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(06): 985-990.
[5] 绳春佳, 陈雨浩, 彭飞, 夏纪凯, 李晓帆, 陈健文, 张楚悦, 吴玲玲, 刘娇娜, 白雪源, 陈香美. 表没食子儿茶素没食子酸酯通过抑制细胞衰老改善小鼠急性肾损伤[J/OL]. 中华肾病研究电子杂志, 2025, 14(03): 133-139.
[6] 杜军霞, 赵小淋, 王浩然, 高志远, 王曼茜, 万楠熙, 张冬, 丁潇楠, 任琴琴, 段颖洁, 汤力, 朱晗玉. 2 型糖尿病的血液透析患者肠道微生物组学高通量测序分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 313-320.
[7] 周楚仪, 王乐今. 先天性眼球震颤相关致病基因及分子遗传学的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(06): 363-367.
[8] 王金龙, 邵敏. 呼吸支持技术:2024 年度进展与展望[J/OL]. 中华重症医学电子杂志, 2025, 11(02): 117-124.
[9] 蔡滨, 郑瑞强. 重症医学科建设:等级医院评审的决定性环节之一[J/OL]. 中华重症医学电子杂志, 2025, 11(02): 130-133.
[10] 吴骎, 王波, 尹万红, 廖雪莲, 郭军, 陶攀, 康焰. 人工智能爆发增长背景下的重症医学发展[J/OL]. 中华重症医学电子杂志, 2025, 11(01): 36-41.
[11] 王谷宜, 黎家琦, 钟燕军, 余波, 吴晨方, 董海云, 徐敏, 王花芹, 唐莉, 朱艳艳, 李金秀, 吕奔. 基于智慧ICU云平台的ARDS集束化管理对ARDS患者临床结局的影响[J/OL]. 中华重症医学电子杂志, 2025, 11(01): 72-77.
[12] 辛宇, 王常松, 于凯江. 重症肾脏:2024年度进展与展望[J/OL]. 中华重症医学电子杂志, 2025, 11(01): 17-21.
[13] 薛明, 吕奔, 邱海波, 杨毅. 中国重症医学质量控制:2024年度进展与展望[J/OL]. 中华重症医学电子杂志, 2025, 11(01): 6-10.
[14] 薛明, 吕奔, 邱海波. 全面提升重症医学医疗服务能力是推进“健康中国”建设的重要支撑[J/OL]. 中华重症医学电子杂志, 2025, 11(01): 1-5.
[15] 王翔, 冯辉斌. 肺部超声在急性呼吸窘迫综合征表型中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(12): 1155-1160.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?